Mechanism of action of steroid hormones and steroid hormone antagonists and their significance for tumor carcinogenesis;Wirkungsmechanismen von Steroidhormonen und Steroidhormonantagonisten und ihre Bedeutung fur die Tumorkarzinogenese

Gynakologe

Volumn 30, Issue 8, 1997, Pages 617-623

  Beckmann, M W ^a   Mohrmann, T ^a   Niederacher, D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT; STEROID HORMONE; STEROID HORMONE ANTAGONIST; TAMOXIFEN;

BREAST CANCER; CARCINOGENESIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; HUMAN; OVARY CANCER; REVIEW;

EID: 0030821877     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001290050158     Document Type: Review

References (90)

1. Barrett-Conner E (1992) Risks and benefits of replacement estrogen. Ann Rev Med 43: 239-251
2. Beatson GT (1896) On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet II: 104-162
3. Beckmann MW, Niederacher D, Schnurch HG, Bender HG (1993) Die erbB-Gen-Familie: Bedeutung für die Tumorentwicklung, Prognose und für neue Therapiemodalitäten. Geburtshilfe Frauenheilkd 53. 742-753
4. Beckmann MW, Niederacher D, Goecke TO, Bodden-Heidrich R, Schnurch HG, Bender HG (1997) Hochrisikofamilien mit Mamma- und Ovarialkarzinomen: Möglichkeiten der Beratung, genetischen Analyse und Früherkennung. Dtsch Ärzteblatt 94: A161-167
5. Beckmann MW, Timmerman D (1997) Gibt es ein Populations- oder Risikogruppenscreening für das Ovariallcarzinom? Gynakologe 30: 85-91
6. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG (1997) Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Molecular Medicine (in press)
7. Belchetz PE (1994) Hormonal treatment of postmenopausal women. N Eng J Med 330: 1062-1071
8. Berkqvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB (1992) Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen-progestogen replacement therapy. Am J Epidem 130. 221-228
9. Bissett D, Davis JA, George WD (1994) Gynaecological monitoring during tamoxifen therapy. Lancet 344: 1244
10. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L (1995) Clinical and biologic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85: 11-17
11. Carmichael PL, Ugwumadu AHN, Neven P, Hewer AJ, Poon GK, Phillips DH (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56: 1475-1479
12. Chapman JA, Di Saia PJ, Osann K, Roth PD, Gillotte DL, Berman ML (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175: 1195-1200
13. Cobleigh MA, Berris RF, Bush T et al. (1994) Estrogen replacement therapy in breast cancer survivors: A time for change. JAMA 272: 540
14. Cohen S, Ellwein L (1991) Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51: 6493-6505
15. Collaborative group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347. 1713-1727
16. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593
17. Colditz GA, Rosner BA, Speizer FE (1996) Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 88: 365-370
18. Colton T, Greenberg R, Noller K et al. (1993) Breast cancer in mothers prescribed diethylstilbestrot in pregnancy. JAMA 269: 2096-2100
19. Cook LS, Weiss KS, Schwartz SM et al. (1995) Population-based study tamoxifen therapy and subsequent ovarian, endometrial, and breast cancer. J Natl Cancer Inst 87: 1359-1364
20. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SB (1996) Endometrial carcinoma associated with breast carcinoma. Cancer 77: 2058-2063
21. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF (1996) Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst 88: 832-834
22. Dati C, Antoniotti S, Taverna O, Perroteau I, De Bortoli M (1990) Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001-1006
23. Deng G, Chen LC, Schott DR et al (1994) Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54: 499-505
24. Dhodapkar MV, Ingle JN, Ahmann DL (1995) Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75: 43-46
25. Di Saia PJ, Grose EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H (1996) Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 147: 1494-1498
26. Di Saia PJ, Odicino F, Grosen EA, Cowan B, Peconelli S, Wile AG (1993) Hormone replacement therapy in breast cancer. Lancet 342. 1232
27. Duncan LJ, Reed MJ (1995) The role of proposed mechanism by which oestradiol 17β hydroxysteroid-dehydrogenase regulates breast tumour oestrogen concentrations. J Steroid Biochem Molec Biol 55 565-572
28. Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 151: 67-72
29. Eden JA, Bush T, Nand S, Wren BG (1995) A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 2: 67-72
30. Emons C, Ortmann O, Schulz KD (1996) Ovulationsinduktion und Karzinomrisiko. Gynakologe 29: 291-299
31. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE (1995) Demethylation of the estrogen receptor gene in estrogen-receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283
32. Fisher B, Constantino JP, Redmond CK et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537
33. Fuqua SAW, Chamness GC, McGuire WL (1993) Estrogen receptor mutations in breast cancer. J Cell Biochem 51. 135-139
34. Fujimoto N, Katzenellenbogen BS (1994) Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen-selectivity and promoter-dependence. Mol Endocrinol 8: 296-304
35. Gambrell RD, Maier RC, Sanders BI (1983) Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62: 35-443
36. Gelmann EP (1996) Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog? J Natl Cancer Inst 88: 24-226
37. Godwin AK, Testa JR, Hamilton TC (1993) The biology of ovarian cancer development. Cancer 71: 530-536
38. Gottardis MM, Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumours in athymic mice after long-term anti-estrogen administration. Cancer Res 48: 5183-5187
39. Grady D, Rubin S, Petitti D et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117 1016-1036
40. Gudas JM, Nguyen H, Li T, Cowan KH (1995) Hormone-dependent regulation of BRCA1 in human cancer cells. Cancer Res 55: 4561-4564
41. Gullick WJ (1990) Growth factors and oncogenes in breast cancer. Progr Growth Factor Res 2: 1-13
42. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M (1994) Estrogen receptor-associatedprotein: possible mediators of hormone-induced transcription. Science 264: 1455-1458
43. Henderson BE, Ross RK, Pike MC (1993) Hormonal chemoprevention of cancer in women. Science 259. 633-638
44. Iwase H, Greenman JM, Barnes DM, Bobrow L, Hodgson S, Mathew CG (1995) Loss of heterozygosity of the estrogen receptor gene in breast cancer. Br J Cancer 71: 448-450
45. Jacobs HS, Loeffler FE (1992) Postmenopausal hormone replacement therapy. Br Med J 305: 1403-1408
46. Jiang SY, Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with cDNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591
47. Johnston SRD, Haynes BP, Smith IE et al. (1993) Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoural drug concentration. Lancet 342: 1521-1522
48. Jones C, Ingram D, Mattes E, Hahnel R (1994) The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Austral 161: 106-110
49. Jordan VC (1990) Estrogen receptor-mediated direct and indirect antitumour effects of tamoxifen. J Nat Cancer Inst 82: 1662-1663
50. Jouvenot M, Pellerin I, Alkhalaf M et al. (1990) Effects of 17β-estradiol and growth factors on C-fos gene expression in endometrial epithelial cells in primary culture. Mol Cell Endocrinol 72: 149-157
51. Kato S, Endoh H, Masuhiro Y et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494
52. Katzenellenbogen BS, Montano MM, Le Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N (1995) Antiestrogens: mechanisms and actions in target cells. J Steroid Biochem Mol Biol 53: 55-64
53. Kedar RP, Bourne HT, Powles T et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321
54. Kuhl H, Runnebaum B, Schneider HPG (1995) Langfristige Hormonsubstitution und Mammakarzinomrisiko: aktuelle Bestandsaufnahme. Frauenarzt 36: 1117-1124
55. Lahooti H, White R, Danielian PS, Parker MG (1994) Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 8: 182-188
56. Lupulescu A (1993) Estrogen use and risk: a review. Exp Clin Endocrin Diabetes 101: 204-214
57. Mangelsdorf DJ, Thummel C, Beato M (1995) The nuclear receptor superfamily: the second decade. Cell 83:8 35-839
58. Markopopoulous C, Berker U, Wilson P, Gazet JC, Coombes RC (1988) Estrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J 296: 1349-51
59. Martin KA, Freeman MW (1993) Postmenopausal hormone replacement therapy. N Engl J Med 328: 1115-1117
60. Nachtigall MJ, Smilen SW, Nachtigall RD, Nachtigall RH, Nachtigall LE (1992) Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80: 827-830
61. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450-1459
62. Ortmann O, Diedrich K, Schulz KD (1997) Hormonelle Substitutionstherapie und gynäkologische Malignome. Gynakologe 30. 326-331
63. Papa M, Mezzogiorno V, Bresciani F, Weisz A (1991) Estrogen induces C-fos expression specifically in the luminal and glandular epithelia of adult rat uterus. Biochem Biophys Res Commun 175: 480-485
64. Pike MC, Spicer DV (1993) The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. J Cellular Biochem 17: 26-36
65. Pollack IF, Kawecki S (1995) The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatr Neurosurg 22. 281-288
66. Poutanen M, Isomaa V, Peitoketo H, Vihko R (1995) Role of β-hydroxysteroid-dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Molec Biol 55: 525-532
67. Powles TJ, Hickish T, Casey S et al. (1993) Hormone replacement after breast cancer. Lancet 342: 60-61
68. Prentice RL (1991) Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancer. Prev Med 20: 38-46
69. Rinehart CA, Xu L, Van Le L, Kaufman DG (1996) Diethylstilbestrol-induced immortalization of human endometrial cells: alterations in p53 and estrogen receptor. Mol Carcinogenesis 15: 115-123
70. Roy JA, Sawka CA, Pritchard KI (1996) Hormone replacement therapy in women with breast cancer: Do the risks outweight the benefits? J Clin Oncol 14. 997-1006
71. Scrocchi LA, Jones LA (1991) Alteration of protooncogene C-fos expression in neonatal estrogenized BALB/c female and murine cervicovaginal tumor LT 6195. Endocrinology 129: 2251-2253
72. Schuchard M, Landers JP, Sandhu NP, Spelsberg TC (1993) Steroid hormone regulation of nuclear proto-oncogens. Endocrine Rev 14: 659-668
73. Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K (1997) Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol 176. 129-137
74. Seeley T (1992) Oestrogen replacement therapy after hysterectomy. Br Med J 305. 811-812
75. Sellers TA, Kushi LH, Potter JD et al. (1992) Effect of family history, body fat distribution and reproductive factors on the risk of breast cancer in premenopausal women. N Engl J Med 326: 1323-1329
76. Smith DC, Prentice R, Thompson DC et al. (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: 1164-1167
77. Stanford JL, Weiss NS, Voigt LF et al. (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274. 137-142
78. Steimberg KK, Thacker SB, Smith SJ et al. (1991) A Meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265: 1985-1990
79. Stoler AB (1991) Genes and cancer. Br Med Bull 47: 64-75
80. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE (1994) erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56: 522-528
81. The writing group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/ progestin intervention (PEPI) trial. JAMA 5: 370-375
82. Theriault RL (1996) Hormone replacement therapy and breast cancer: an overview. Br J Obstet Gynecol 103: 87-91
83. Van Leeuwen FE, Rookus MA (1989) The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. Eur J Cancer Clin Oncol 25: 1961-1972
84. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G (1991) Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338: 274-277
85. Wales MM, Biel MA, Deiry WE et al. (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1995: 570-577
86. Waxman J (1991) A new understanding of the hormonal regulation endocrine dependent cancer. Br Med Bull 47: 197-208
87. Warri AM, Laine AM, Majasuo KE, Alitalo KK, Harkonen PL (1991) Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer 49: 616-623
88. Westley B, May FEB (1993) Mechanism of anti-oestrogen resistance in cancer cells. Cancer Topics 9: 39-41
89. Wile AG, Opfell RW, Margileth DA (1993) Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165: 372-375
90. Zwijsen RM, Wientjens E, Klompmaker R, vab der Sman J, Bernards R, Michalises RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415